Related Experiment Videos
Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase
1Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA. mcaruso@bcm.tmc.edu
Abstract:
The expression of the gene encoding herpes simplex virus thymidine kinase (HSV-TK) in eukaryotic cells confers sensitivity to antiherpetic drugs such as acyclovir and ganciclovir. This property has been proposed for use in gene therapy approaches to kill either cancer cells or HIV-infected cells. Several animal experiments have shown the regression of tumors after in vivo transfer of the HSV-TK gene followed by ganciclovir treatment. Furthermore, CD4+ T cells harboring the HSV-TK gene under the control of HIV regulatory sequences are protected from HIV spreading in the presence of acyclovir. Thus, the HSV-TK gene has potential applications in gene therapy for the treatment of cancer and HIV infection.
Insights
The herpes simplex virus thymidine kinase (HSV-TK) gene enables gene therapy for cancer and HIV. HSV-TK confers drug sensitivity, allowing targeted killing of cancer cells or blocking HIV spread in T cells.
Area of Science:
- Molecular Biology
- Gene Therapy
- Virology
Background:
- The herpes simplex virus thymidine kinase (HSV-TK) gene confers sensitivity to specific antiviral drugs.
- This characteristic has been explored for therapeutic applications in gene therapy.
Purpose of the Study:
- To evaluate the potential of the HSV-TK gene in gene therapy for cancer and HIV infection.
- To summarize the efficacy of HSV-TK gene transfer in preclinical models.
Main Methods:
- In vivo transfer of the HSV-TK gene into animal models.
- Administration of antiviral drugs (ganciclovir or acyclovir) post-gene transfer.
- Monitoring tumor regression in cancer models.
- Assessing protection of CD4+ T cells from HIV replication.
Main Results:
- Animal experiments demonstrated tumor regression following HSV-TK gene transfer and ganciclovir treatment.
- CD4+ T cells engineered with HSV-TK were protected from HIV spread when treated with acyclovir.
Conclusions:
- The HSV-TK gene holds significant potential for gene therapy applications.
- It can be utilized to target and eliminate cancer cells or inhibit HIV propagation.